Page last updated: 2024-12-06
valofane
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Description
valofane: neurotropic drug; RN given refers to cpd with unspecified isomeric designation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 71122 |
| CHEMBL ID | 2104479 |
| SCHEMBL ID | 715189 |
| MeSH ID | M0040226 |
Synonyms (30)
| Synonym |
|---|
| valofan |
| 2-allophanoyl-2-allyl-4-pentanolid |
| valofane |
| alpha-allophanoyl-alpha-allyl-gamma-valerolacton |
| ureid kwasu 4-allilo-2-metylo-tetrahydro-furan-5-on-4-karboksylowego [polish] |
| 3-furancarboxamide, n-(aminocarbonyl)tetrahydro-5-methyl-2-oxo-3-(2-propenyl)- |
| (3-allyltetrahydro-5-methyl-2-oxo-3-furoyl)urea |
| malonamic acid, 2-allyl-n-carbamoyl-2-(2-hydroxypropyl)-, gamma-lactone |
| hh 10018 |
| valofane [inn] |
| ureide of 4-allyl-2-methyltetrahydrofuran-5-one-4-carboxylic acid |
| urea, (3-allyltetrahydro-5-methyl-2-oxo-3-furoyl)- |
| einecs 221-857-9 |
| brn 1431729 |
| valofanum [latin] |
| valofano [spanish] |
| n-carbamoyl-5-methyl-2-oxo-3-prop-2-enyloxolane-3-carboxamide |
| 3258-51-3 |
| valofanum |
| unii-x71n6e5ipo |
| ureid kwasu 4-allilo-2-metylo-tetrahydro-furan-5-on-4-karboksylowego |
| valofano |
| 5-18-08-00081 (beilstein handbook reference) |
| x71n6e5ipo , |
| CHEMBL2104479 |
| SCHEMBL715189 |
| 2-allophanyl-2-allyl-gamma-valerolactone |
| Q7912521 |
| DTXSID20863139 |
| AKOS040747568 |
Research Excerpts
Pharmacokinetics
| Excerpt | Reference | Relevance |
|---|---|---|
| " The distribution and kinetics of the two compounds appeared to obey a single compartment system with a half-life of approximately one hour." | ( Pharmacokinetics of 14C-2-allophanyl-2-allyl -gamma-valero-lactone: a prodrug of proxibarbal in rats. Compagnon, PL; Jacquot, C; Lambrey, B, 1981) | 0.26 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (2)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 2 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||